Celsion Corporation (NASDAQ:CLSN) – Griffin Securities lifted their Q3 2017 earnings per share estimates for Celsion Corporation in a note issued to investors on Wednesday. Griffin Securities analyst K. Markey now anticipates that the biotechnology company will post earnings per share of ($0.43) for the quarter, up from their prior estimate of ($0.68). Griffin Securities also issued estimates for Celsion Corporation’s Q4 2017 earnings at ($0.39) EPS, FY2017 earnings at ($2.44) EPS, Q1 2018 earnings at ($0.32) EPS, Q2 2018 earnings at ($0.24) EPS, Q3 2018 earnings at ($0.25) EPS, Q4 2018 earnings at ($0.25) EPS and FY2018 earnings at ($1.04) EPS.

ILLEGAL ACTIVITY NOTICE: “Q3 2017 EPS Estimates for Celsion Corporation Increased by Griffin Securities (CLSN)” was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another publication, it was stolen and reposted in violation of international trademark and copyright legislation. The correct version of this news story can be read at https://www.americanbankingnews.com/2017/08/18/q3-2017-eps-estimates-for-celsion-corporation-increased-by-griffin-securities-clsn.html.

A number of other equities research analysts have also weighed in on CLSN. Maxim Group reissued a “hold” rating on shares of Celsion Corporation in a research note on Thursday, April 20th. Zacks Investment Research raised Celsion Corporation from a “hold” rating to a “buy” rating and set a $3.50 target price for the company in a research note on Wednesday, April 26th. Finally, ValuEngine raised Celsion Corporation from a “sell” rating to a “hold” rating in a research note on Wednesday, May 31st. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $25.38.

Shares of Celsion Corporation (CLSN) opened at 1.35 on Friday. Celsion Corporation has a 52 week low of $1.26 and a 52 week high of $19.60. The stock has a 50 day moving average price of $1.73 and a 200 day moving average price of $1.02. The firm’s market cap is $11.27 million.

A hedge fund recently raised its stake in Celsion Corporation stock. Renaissance Technologies LLC increased its position in shares of Celsion Corporation (NASDAQ:CLSN) by 396.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 684,798 shares of the biotechnology company’s stock after buying an additional 546,813 shares during the period. Renaissance Technologies LLC owned about 2.63% of Celsion Corporation worth $208,000 as of its most recent filing with the SEC. Institutional investors own 91.57% of the company’s stock.

About Celsion Corporation

Celsion Corporation is an oncology drug development company. The Company’s product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study).

Earnings History and Estimates for Celsion Corporation (NASDAQ:CLSN)

Receive News & Ratings for Celsion Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion Corporation and related companies with MarketBeat.com's FREE daily email newsletter.